FibroBiologics received three patents from the USPTO for cartilage repair, disc degenerative disease treatment, and chondrocyte regeneration.
FibroBiologics, a Houston-based clinical-stage biotechnology company, announced the issuance of three patents from the US Patent Office, expanding its portfolio and taking the total number of issued and pending patents to over 150. The patents cover methods and compositions for repairing cartilage, treating disc degenerative disease, and gene therapy for regenerating chondrocytes or cartilage cells.
February 08, 2024
4 Articles